Volastra Therapeutics , a NYC-based biotechnology company developing novel therapies for the treatment of metastatic cancers, raised $12m in funding. The round was led by Polaris Partners with participation from DROIA Oncology Ventures, the Global Health Sciences (GHS) Fund (Quark Venture LP and GF Securities), and ARCH Venture Partners. […]
View Original Source at Volastra Therapeutics Raises $12M in Seed Financing